The activation of the Nrf2 pathway in liver cancer cells can upregulate the expression of metallothionein-1G (MT-1G) and promotes sorafenib drug resistance by inhibiting ferroptosis (Roh et al., 2017). This evidence concerns the gene MT1G and liver cancer.